Capricor Therapeutics Inc (CAPR)

[staccani]

https://endpts.com/sareptas-exondys-51-is-not-cost-effective-nor-particularly-beneficial-to-dmd-patients-icer/. Eteplirsen is basically the only not particularly effective drug for a part for patients with DMD, priced at almost $900K average per patient per year. The drug was approved based on 12 patients trial. Eteplirsen had $300M sales last year (fist full year after introduction) and $94M sales in q2 2019. I think Capricor has good chances to be approved based on the shown results and to surpass by far Eterplisen sales. Place your bets